Similar articles

Abstract: To conduct a systematic review of group studies assessing the association of serum vitamin D status with the severity of liver fibrosis in chronic hepatitis C patients using meta-analysis. The relevant research literatures were identified by searching PubMed and EMBASE databases prior to October 2013 with no restrictions. We included group studies that reported odds ratio (OR) estimates with 95% confidence intervals (CIs) or a mean with standard deviation (SD) for the association between serum vitamin D status and the severity of liver fibrosis in chronic hepatitis C patients. Approximately 8321 participants from several countries were included in this analysis. Six studies on serum vitamin D status and the severity of liver fibrosis were included in this meta-analysis. ORs with 95% CIs were extracted from four studies and the pooled ORs were 0.866 (95% CI, 0.649 to 1.157). The means with SDs were extracted from three studies and the pooled means were −0.487 (95% CI, −0.659 to −0.315). There was statistically significant heterogeneity among the mean data extracted studies (P=0.029; I ²=71.8%) but not among the OR data extracted studies (P=0.061; I ²=55.6%). Finally, results from the mean data extracted studies suggest that lower serum vitamin D is a risk factor for the severity of liver fibrosis in chronic hepatitis C patients. However, there is no conclusive evidence on this association because of inconsistencies between the OR data extracted studies and the mean data extracted studies.

慢性丙型肝炎患者的血清维生素D与严重肝纤维化相关性研究：系统性的荟萃分析

研究目的：利用meta分析方法来探索慢性丙型肝炎患者低血清维生素D水平与严重肝纤维化相关性。
创新要点：丙型病毒性肝炎病人的低血清维生素D水平与严重肝纤维化并不一定有相关性。
研究方法：结合已发表的临床研究数据，采用荟萃分析方法，定量分析低血清维生素D水平与慢性丙型肝炎患者严重肝纤维化相关性（图2；表2）。
重要结论：此荟萃分析对于认识丙型肝炎病人低血清维生素D水平与肝纤维化严重程度的相关性有重要 意义，对未来相关临床研究具有指导意义。
维生素D；纤维化；丙型病毒性肝炎；荟萃分析

[1] Amanzada, A., Goralczyk, A.D., Moriconi, F., 2013. Vitamin D status and serum ferritin concentration in chronic hepatitis C virus type 1 infection. J Med Virol, 85(9):1534-1541. 

[2] Arteh, J., Narra, S., Nair, S., 2010. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci, 55(9):2624-2628. 

[3] Baeke, F., Takiishi, T., Korf, H., 2010. Vitamin D: modulator of the immune system. Curr Opin Pharmacol, 10(4):482-496. 

[4] Baur, K., Mertens, J.C., Schmitt, J., 2012. Combined effect of 25-OH vitamin D plasma levels and genetic Vitamin D Receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int, 32(4):635-643. 

[5] Cholongitas, E., Theocharidou, E., Goulis, J., 2012. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. Alimen Pharmacol Ther, 35(6):634-646. 

[6] Clemens, T.L., Henderson, S.L., Adams, J.S., 1982. Increased skin pigment reduces the capacity of skin to synthesise vitamin D₃ . Lancet, 319(8263):74-76. 

[7] Corey, K.E., Zheng, H., Mendez-Navarro, J., 2012. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS ONE, 7(2):e27144

[8] Egger, M., Davey, S.G., Schneider, M., 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109):629-634. 

[9] Geier, A., 2011. Shedding new light on vitamin D and fatty liver disease. J Hepatol, 55(2):273

[10] Hennekens, C.H., Demets, D., 2009. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA, 302(21):2361-2362. 

[11] Hewison, M., 2010. Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol, 321(2):103-111. 

[12] Hintzpeter, B., Scheidt-Nave, C., Mller, M.J., 2008. Higher prevalence of vitamin D deficiency is associated with immigrant background among children and adolescents in Germany. J Nutr, 138(8):1482-1490. 

[13] Holick, M.F., Chen, T.C., 2008. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr, 87(4):1080S-1086S. 

[14] Holick, M.F., Chen, T.C., Lu, Z., 2007. Vitamin D and skin physiology: a D-lightful story. J Bone Miner Res, 22(Suppl. 2):V28-V33. 

[15] Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., 2011. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 96(7):1911-1930. 

[16] Hoofnagle, J.H., 2002. Course and outcome of hepatitis C. Hepatology, 36(5 Suppl. 1):S21-S29. 

[17] Kitson, M.T., Dore, G.J., George, J., 2013. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol, 58(3):467-472. 

[18] Ladero, J.M., Torrejn, M.J., Snchez-Pobre, P., 2013. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ann Hepatol, 12(2):199-204. 

[19] Lange, C.M., Bojunga, J., Ramos-Lopez, E., 2011. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol, 54(5):887-893. 

[20] Lange, C.M., Miki, D., Ochi, H., 2013. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS ONE, 8(5):e64053

[21] Micallef, J.M., Kaldor, J.M., Dore, G.J., 2006. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat, 13(1):34-41. 

[22] Petta, S., Camm, C., Scazzone, C., 2010. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 51(4):1158-1167. 

[23] Petta, S., Grimaudo, S., Marco, V.D., 2013. Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Viral Hepatitis, 20(7):486-493. 

[24] Poynard, T., Yuen, M.F., Ratzin, V., 2003. Viral hepatitis C. Lancet, 362(9401):2095-2100. 

[25] Romero-Gmez, M., Viloria, M.D.M., Andrade, R.J., 2005. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology, 128(3):636-641. 

[26] Shepard, C.W., Finelli, L., Alter, M.J., 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis, 5(9):558-567. 

[27] Stokes, C.S., Volmer, D.A., Grnhage, F., 2013. Vitamin D in chronic liver disease. Liver Int, 33(3):338-352. 

[28] Terrier, B., Jehan, F., Munteanu, M., 2012. Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. Rheumatology, 51(11):2083-2090. 

[29] Thomas, D.L., Seeff, L.B., 2005. Natural history of hepatitis C. Clin Liver Dis, 9(3):383-398. 

[30] Tong, J., Wang, Y.W., Lu, Y.A., 2012. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 13(1):56-82. 

[31] Villar, L.M., Del Campo, J.A., Ranchal, I., 2013. Association between vitamin D and hepatitis C virus infection: a meta-analysis. World J Gastroenterol, 19(35):5917

[32] von Essen, M.R., Kongsbak, M., Schjerling, P., 2010. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol, 11(4):344-349. 

[33] Wang, T.T., Nestel, F.P., Bourdeau, V., 2004. Cutting edge: 1,25-dihydroxyvitamin D₃ is a direct inducer of antimicrobial peptide gene expression. J Immunol, 173(5):2909-2912. 

[34] Weintraub, S.J., Fleckenstein, J.F., Marion, T.N., 2012. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. Am J Clin Nutr, 96(5):1025-1031. 

[35] White, D.L., Tavakoli-Tabasi, S., Kanwal, F., 2013. The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Aliment Pharmacol Ther, 38(1):28-37. 

[36] Zhu, Y., Zheng, Y., Shen, Y.Y., 2014. Analyzing and modeling rheological behavior of liver fibrosis in rats using shear viscoelastic moduli. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 15(4):375-381.